Bioventus said it acquired the OsteoAMP product line from Advanced Biologics for an undisclosed amount.
OsteoAMP is a tissue-based product used to promote natural bone growth and healing in the spine, according to a press release.
Mindray Medical (NYSE:MR) chief Li Xiting will share the corner office, so to speak, with new co-CEO Cheng Minghe, who takes the new title in addition to continuing as the company’s chief strategic officer.
Cheng is one of the founders of the Shenzhen, China-based company, and has worked in various roles since 1991.
MRI Interventions (OTC:MRIC), a company developing minimally invasive neurosurgery systems, launched an initial public offering with shares at $1 apiece.
The Memphis-based company’s flagship ClearPoint technology allows patients to undergo surgery during MRI scanning, using the images to target areas of the brain for surgery.
British orthopedic titan Smith & Nephew (NYSE:SNN) shuffled its business deck yet again with the spinout of its biologics and clinical therapies division in a joint venture with venture capital firm Essex Woodlands.
Essex will own 51% of the new business, named Bioventus LLC, with Smith & Nephew holding the remainder.
SNN will also get $98 million in cash, which it plans to use to pay down debt, and a $160 million, 5-year note from Bioventus, according to a press release.